LOCUS       sequence-98429-e        1037 bp    DNA     linear   UNA 15-DEC-2025
DEFINITION  Expressed murine IFITM3-C72,105A with an N-terminal HA tag in 
            mammalian cells.
ACCESSION   .
VERSION     .
KEYWORDS    .
SOURCE      natural DNA sequence
  ORGANISM  unspecified
REFERENCE   1  (bases 1 to 1037)
  AUTHORS   Yount JS, Moltedo B, Yang YY, Charron G, Moran TM, Lopez CB, Hang HC
  TITLE     Palmitoylome profiling reveals S-palmitoylation-dependent antiviral 
            activity of IFITM3.
  JOURNAL   Nat Chem Biol. 2010 Aug;6(8):610-4. doi: 10.1038/nchembio.405. Epub 
            2010 Jul 4.
  PUBMED    20601941
REFERENCE   2  (bases 1 to 1037)
  AUTHORS   .
  TITLE     Direct Submission
  JOURNAL   Exported Dec 15, 2025 from SnapGene Server 8.0.1
            https://www.snapgene.com
COMMENT     SGRef: number: 1; type: "Journal Article"; doi: 
            "10.1038/nchembio.405"; journalName: "Nat Chem Biol"; date: 
            "2010-08"; volume: "6"; issue: "8"; pages: "610-4"
COMMENT     Sequence Label: pCMV-HA-mIFITM3-C72,105A
FEATURES             Location/Qualifiers
     source          1..1037
                     /mol_type="genomic DNA"
                     /organism="unspecified"
     CDS             complement(483..509)
                     /codon_start=1
                     /product="HA (human influenza hemagglutinin) epitope tag"
                     /label=HA
                     /translation="YPYDVPDYA"
     intron          573..669
                     /label=SV40 intron
                     /note="modified SV40 intron with splice donor and acceptor 
                     sites"
     primer_bind     complement(786..810)
                     /label=LNCX
                     /note="Human CMV promoter, forward primer"
     promoter        complement(807..1010)
                     /label=CMV promoter
                     /note="human cytomegalovirus (CMV) immediate early 
                     promoter"
     primer_bind     complement(836..856)
                     /label=CMV-F
                     /note="Human CMV immediate early promoter, forward primer"
ORIGIN
        1 ggatccccgc ggccgcggta cctcgagaga tctcggtcga cttaagtgtg aaggttttga
       61 gcgttaagaa caatgatgat gacactaaca atggtgataa caaccatcag gatgctgagg
      121 accaaggtgc tgatgttcag tgccttagca gtggaggcgt aggcctgggc tccagtcaca
      181 tcacccacca tcttccgatc cctagacttc acggagtagg cataggctat gaagcccagt
      241 gcgcagaagt tcatgaagag tgtattgaac agggaccaga ccacatggtc aggcaccgac
      301 acctctctgg gcatgttgat cacagtagtt ctgacagaag ccgatccgtg cggtgccccc
      361 atctcagcca cctcatattc ttccttgatt ctttcgtagt ttgggggctg tcctccactg
      421 gcagcggtga tgaaggcttg agaagtgtgg ttcatgggaa ttcgggcctc catggccata
      481 agagcgtaat ctggaacatc gtatgggtac atggtgggcc cgcgggtaca attccgcagc
      541 ttttagagca gaagtaacac ttccgtacag gcctagaagt aaaggcaaca tccactgagg
      601 agcagttctt tgatttgcac caccaccgga tccgggacct gaaataaaag acaaaaagac
      661 taaacttacc agttaacttt ctggtttttc agttcctcta gtaccggatc ctctagagtc
      721 cggaggctgg atcggtcccg gtgtcttcta tggaggtcaa aacagcgtgg atggcgtctc
      781 caggcgatct gacggttcac taaacgagct ctgcttatat agacctccca ccgtacacgc
      841 ctaccgccca tttgcgtcaa tggggcggag ttgttacgac attttggaaa gtcccgttga
      901 ttttggtgcc aaaacaaact cccattgacg tcaatggggt ggagacttgg aaatccccgt
      961 gagtcaaacc gctatccacg cccattgatg tactgccaaa accgcatcac catggtaata
     1021 gcgatgacta atacgta
//
